Your central resource for PET educational materials, including evidence-based publications, clinical case studies, and product resources. Check out the new SOFIE Education Hub Go to the education hub
In 2006, the creation of SOFIE launched the aspiration of having a multifaceted approach to expand the reach of PET products for patients with advanced imaging needs. This was further realized in 2017.
SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible. Our product lines include FDG, Pylarify, Neuraceq, and.
Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites. View SOFIE’s Link here View our Privacy Policy
In Nov 2019, SOFIE Biosciences (SOFIE) licensed quinoline-based PET tracers, developed by the team at Heidelberg University, that act as FAP inhibitors (FAPI) and showed promising clinical data in a.
GE HealthCare and SOFIE Biosciences (SOFIE) announced a partnership to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation.
SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies
Dec 29, 2025 · With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high-value theranostic intellectual property, SOFIE is poised to.
